According to Future Market Insights, Myelofibrosis (MF) Treatment Market is expected to grow at a CAGR of 5.5% between 2023 and 2033, reaching US$ 1,280 Million by 2033. Sales grew at a CAGR of 5.2% from 2018 to 2023. Patients with myelofibrosis can be treated using a variety of methods, depending on their condition and symptoms. A number of treatment options are available, including chemotherapy, targeted drug therapy, surgery, radiation therapy, and stem cell transplants. JAK inhibitors may be included in future myelofibrosis treatment niches, as well as JAK inhibitor combination therapies in the first and second lines of treatment.
Anemia is one of the most common complications of MF patients. Most patients with anemia are anemic at the time of diagnosis, and nearly all will develop anemia in the future. In recent clinical studies, researchers have investigated a new approach to reducing iron levels by inhibiting a protein called hepcidin. Anaemia can be caused by high levels of hepcidin, which prevents iron absorption.
Get a PDF Sample with Latest Market Insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16296
Various governmental and non-governmental organizations are expected to introduce new innovative products to the market. The development of oral drugs for treating myelofibrosis is currently being studied in different ways. A PERSIST-2 trial supporting the approval of pacritinib used data from patients who received either pacritinib or the best available therapy (BAT). The PACIFICA study is expected to have results in the middle of 2025 and will be part of the accelerated approval process. Diarrhea, thrombocytopenia, nausea, anemia, and peripheral edema were the most common adverse reactions associated with pacritnib twice daily.
Key Takeaways from the Market Study
- The global market size for myelofibrosis is estimated to reach US$ 749.05 billion by 2023.
- According to the forecast, the market is expected to grow by 5.5% between 2023 and 2033, reaching a total of US$ 1,280 Million by 2033.
- Oral myelofibrosis treatment to account for 33% of the total market value in 2023.
- Myelofibrosis in North America expanded with a market share of 53% in 2022.
- The hospital pharmacy market is expected to account for 38% of total market value by 2023.
Ask from Market Research Expert@ https://www.futuremarketinsights.com/ask-question/rep-gb-16296
“New oral drugs and devices are being approved as chronic cancer becomes more prevalent, and artificial intelligence and technology will play a significant role in growing drug delivery methods.” comments a Future Market Insights analyst.
Competitive Landscape
Many companies are expected to focus their efforts on developing innovative diagnostic techniques in the near future, resulting in the expansion of their product lines, the acquisition of other companies, and the merger of their companies.
- Karyopharm Therapeutics Inc., As a commercially-stage pharmaceutical company developing novel cancer treatments, the 64th American Society of Hematology (ASH) Annual Meeting and Exposition will feature a webcast to provide updates on the Phase 1 open-label, ruxolitinib combination study in myelofibrosis patients who have yet to receive treatment.
- As part of the 64th American Society of Hematology (ASH®) Annual Meeting and Exposition, CTI BioPharma Corp. will present two oral presentations and a poster presentation about its pacritinib program in New Orleans, Louisiana and virtually from December 10-13, 2022. PERSIST-2, a Phase 3 study of pacritinib, a novel JAK2/IRAK1 inhibitor approved by the U.S. Food and Drug Administration (FDA) for the treatment of severe thrombocytopenia (platelets under 50 x 109/L) in patients with myelofibrosis, demonstrates the drug’s potential anemia benefit by inhibiting Activin A receptor type 1 (ACVR1).
For more Report Customization, connect with us at@ https://www.futuremarketinsights.com/customization-available/rep-gb-16296
Key Companies Profiled:
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- Mylan N.V.
- Fresenius Kabi AG
- Hikma Pharmaceuticals PLC
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Bristol Myers Squibb Company
- GSK Plc.
- Bayer AG
- Sun Pharmaceutical Industries Ltd
- Boehringer Ingelheim International Gmbh
- Sanofi
Key Segments Profiled in the Myelofibrosis Market Industry Survey?
By Treatment Type:
- Targeted Therapy
- Chemotherapy
- Others
By Route of Administration:
- Oral
- Parenteral
- Others
By End User:
- Hospitals
- Homecare
- Specialty Clinics
- Others
By Distribution Channel:
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Gain Immediate Access to Detailed Market Insights@
https://www.futuremarketinsights.com/checkout/16296
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa (MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
